Percheron Therapeutics Limited

ASX:PER Voorraadrapport

Marktkapitalisatie: AU$70.3m

Percheron Therapeutics Balans Gezondheid

Financiële gezondheid criteriumcontroles 6/6

Percheron Therapeutics has a total shareholder equity of A$9.4M and total debt of A$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are A$14.5M and A$5.2M respectively.

Belangrijke informatie

0%

Verhouding schuld/eigen vermogen

AU$0

Schuld

Rente dekkingsration/a
ContantAU$11.87m
AandelenAU$9.36m
Totaal verplichtingenAU$5.17m
Totaal activaAU$14.53m

Recente financiële gezondheidsupdates

Recent updates

We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

Jun 03
We Think Percheron Therapeutics (ASX:PER) Needs To Drive Business Growth Carefully

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Nov 13
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

Jun 08
We're Not Very Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Rate

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Feb 14
We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Aug 26
We're Hopeful That Antisense Therapeutics (ASX:ANP) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

May 12
Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Dec 23
We Think Antisense Therapeutics (ASX:ANP) Needs To Drive Business Growth Carefully

Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

Jun 24
Here's Why We're Not Too Worried About Antisense Therapeutics' (ASX:ANP) Cash Burn Situation

We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Mar 11
We Think Antisense Therapeutics (ASX:ANP) Can Afford To Drive Business Growth

Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Nov 26
Will Antisense Therapeutics (ASX:ANP) Spend Its Cash Wisely?

Analyse van de financiële positie

Kortlopende schulden: PER's short term assets (A$14.5M) exceed its short term liabilities (A$5.2M).

Langlopende schulden: PER's short term assets (A$14.5M) exceed its long term liabilities (A$15.2K).


Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: PER is debt free.

Schuld verminderen: PER had no debt 5 years ago.


Balans


Analyse van de cashflow

Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.

Stabiele cash runway: PER has sufficient cash runway for more than a year based on its current free cash flow.

Voorspelling contante baan: PER is forecast to have sufficient cash runway for 8 months based on free cash flow estimates, but has since raised additional capital.


Ontdek gezonde bedrijven